Chelsea Therapeutics, Inc. Presents Efficacy And Safety Data For NORTHERA At International Congress Of Parkinson's Disease And Movement Disorders

CHARLOTTE, N.C. and STOCKHOLM, Sweden, June 12, 2014 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) today announced the presentation of an integrated analysis of data from two pivotal multicenter, placebo-controlled, randomized clinical trials showing that NORTHERA™ (droxidopa) had demonstrated an acceptable safety profile and demonstrated a statistically significant difference in efficacy compared to placebo for improving the symptoms of neurogenic orthostatic hypotension (NOH) in a population comprised chiefly of patients with Parkinson's Disease (PD). The results were presented at the 18th International Congress of Parkinson's Disease and Movement Disorders (MDS) in Stockholm, Sweden, June 8-12, 2014.

Help employers find you! Check out all the jobs and post your resume.